Identification and verification of characteristic differentially expressed ferroptosis-related genes in osteosarcoma using bioinformatics analysis-Reference-Cited by-同舟云学术

Identification and verification of characteristic differentially expressed ferroptosis-related genes in osteosarcoma using bioinformatics analysis

Published:2023-08-08 Issue:9 Volume:33 Page:781-795
ISSN:1537-6516
Container-title:Toxicology Mechanisms and Methods
language:en
Short-container-title:Toxicology Mechanisms and Methods

Author:

Hu Jianhua¹²,Yang Xi¹³,Ren Jing⁴,Zhong Shixiao²³,Fan Qianbo²³,Li Weichao¹²³

Affiliation:

1. Department of Orthopedic Surgery, The First People’s Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, P. R. China

2. Faculty of Medical Science, Kunming University of Science and Technology, Kunming, P. R. China

3. Yunnan Key Laboratory of Digital Orthopaedics, Kunming, P. R. China

4. Department of Spinal Surgery, Qujing No. 1 Hospital, Affiliated Qujing Hospital of Kunming Medical University, Qujing, P. R. China

Funder

the National Natural Science Foundation of China

Key Research Project of Yunnan Provincial Science and Technology

Key project of Yunnan clinical medicine research center

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Toxicology

Link

https://www.tandfonline.com/doi/pdf/10.1080/15376516.2023.2240879

Reference84 articles.

1. Prediction of kinase inhibitors binding modes with machine learning and reduced descriptor sets

2. The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies

3. Viral metagenomic analysis of fecal samples reveals an enteric virome signature in irritable bowel syndrome

4. Acute Urticaria in Inpatients Undergoing Non-emergent Coronary Angiography With Corticosteroid Prophylaxis: A Retrospective Study

5. The Prognostic Model Established by the Differential Expression Genes Based on CD8+ T Cells to Evaluate the Prognosis and the Response to Immunotherapy in Osteosarcoma